Mark James Litton - Oct 3, 2024 Form 4/A - Amendment Insider Report for Athira Pharma, Inc. (ATHA)

Role
President and CEO, Director
Signature
/s/ Mark Worthington, Attorney-in-Fact for Mark James Litton
Stock symbol
ATHA
Transactions as of
Oct 3, 2024
Transactions value $
$0
Form type
4/A - Amendment
Date filed
10/3/2024, 09:50 PM
Date Of Original Report
Oct 3, 2024
Previous filing
Sep 5, 2024
Next filing
Jan 3, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +325K $0.00 325K Oct 3, 2024 Common Stock 325K $0.43 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4 incorrectly reported the Exercise Price as $0.4499.
F2 One-third (1/3rd) of the shares subject to the option shall vest on each of December 31, 2024, June 30, 2025 and December 31, 2025, subject to the Reporting Person continuing to be a Service Provider through the applicable vesting dates.